LANDRY
CANCER BIOLOGY
CONSORTIUM

ANNUAL SPRING SYMPOSIUM 2022

THURSDAY JUNE 16
12-6:30pm

featuring
KARIN GRUNEBAUM
CANCER RESEARCH FOUNDATION
POSTER COMPETITION

TABLE OF CONTENTS

LANDRY CANCER BIOLOGY CONSORTIUM – WHO WE ARE

The Landry Cancer Biology Consortium is an educational consortium that aims to bring together the cancer biology community at Harvard and its affiliates. We seek to provide advanced training and opportunities for students to extend their studies and community beyond the classroom and thesis lab. The overarching mission of the Landry Cancer Biology Consortium is **to provide a framework for multidisciplinary approaches to cancer and expose a broader range of minds at every level of training to the challenges of cancer research** and thus achieve a more multidisciplinary perspective – spurring the kind of innovative, non-traditional ideas that often result from recruiting new kinds of expertise.

WE ACHIEVE OUR MISSION –

- By providing **a competitive research fellowship** to graduate students that includes tuition and stipend benefits
- By planning and designing **cancer-related curriculum**
- By planning, organizing, and executing **professional development opportunities** in order to foster the development of the future leaders in cancer biology

This work is made possible by the generous support to Harvard Faculty of Arts and Sciences of the late C. Kevin Landry and his family, colleagues, and friends. This gift represents a transformative investment in some of the best and brightest young minds in cancer biology. Through the Landry Cancer Biology Consortium, Harvard is leveraging the strength of its scientific community to encourage new breakthroughs in cancer research and treatment.

CONNECT WITH US

If you want to learn more about Landry Cancer Biology Consortium, visit our website https://landrycancer.hms.harvard.edu.

Follow us on Twitter @LandryCancerBio

If you have any questions don't hesitate to reach out to Jelena Patrnogić, Jelena_Patrnogic@hms.harvard.edu

KARIN GRUNEBAUM CANCER RESEARCH FOUNDATION

Additional support for cancer biology program at Harvard comes from the Karin Grunebaum Cancer Research Foundation (KGCRF), **established in 1958 in loving memory of Karin Grunebaum** by her husband, Fritz Grunebaum, in order to invest in researchers who have made cancer research their life's work.

KGCRF MISSION

Because Karin Grunebaum died at age 39 from an unknown primary site malignancy, the overriding objective of the Karin Grunebaum Cancer Research Foundation is the eradication of all types of cancer. The Foundation's original Declaration of Trust, written in 1958, mandates that the Foundation's funds be exclusively used for **"...aiding research in and study of the cause, treatment and cure of cancer."**

The Foundation's Trustees firmly believe that the eradication of cancer will only occur through successful research accomplishments which are followed by successful practical/commercial application. Thus, **the Foundation has chosen to invest its funds directly in dedicated cancer researchers in hope of helping them achieve significant accomplishments to eliminate all types of carcinomas and thereby eradicate each and every type of cancer.**

If you want to learn more about the Karin Grunebaum Cancer Research Foundation, visit the website https://www.grunebaumfoundation.org.

KGCRF SUPPORT FOR PROFESSIONAL DEVELOPMENT AT HARVARD

The Foundation's slogan is "*Over 60 years of developing cancer researchers*" and their generous gift to the graduate training at Harvard directly supports professional development of our students. Since 2017, the funds are used for a graduate student poster competition held annually during the Spring Symposium where cancer biology trainees have the opportunity to compete for **KGCRF Professional Development Awards**. In addition to the KGCRF Professional Development Awards, KGCRF's generous gift provides fund to support our newly developed **Karin Grunebaum Career Catalyst Awards** (KGCCA). The KGCCA are designed to support student professional development training by providing opportunities to enhance and expand the scope of their research through new collaborations, skills and knowledge. The KGCCA aim to fund student-conceived proposals that complement, and directly impact their ongoing thesis research, or bring new approaches to the research questions through establishing collaborations.

SYMPOSIUM SCHEDULE

KARIN GRUNEBAUM CANCER RESEARCH FOUNDATION POSTER COMPETITION

Gordon Hall 106 Waterhouse Conference Room

12 – 2pm Poster session

SEMINARS

TMEC 227

2:15 – 2:20pm Introduction & Welcome

2:20 – 2:35pm Spatially mapping T cell receptors and transcriptomes
Sophia Liu, Fei Chen Lab

2:35 – 2:50pm Massively Parallel Profiling of Protein-coding Variants in Transcription Factors with SCAnnEd
Ceejay Lee, Brian Liau Lab

2:50 – 3:05pm Combinatorial strategies to target *NRAS*-mutant melanoma
Lisa Situ, Karen Cichowski Lab

3:05 – 3:20pm Visualizing CD8+ T cell infiltration in a zebrafish model of melanoma
Georgia Stirtz, Leonard Zon Lab

3:20 – 3:35pm A conserved transcription elongation factor mediates DNA replication and genome stability
Catherine Miller, Fred Winston Lab

3:35 – 3:50pm Oncogenic K-Ras suppresses global miRNA function
Bing Shui, Kevin Haigis Lab

3:50 – 4:05pm The Effects of Gly12 KRAS Oncogenes are Mutation and Context Specific
Shikha Sheth, PhD, former graduate student, Kevin Haigis Lab

4:05 – 4:15pm Break

4:15 – 5:15pm **Keynote lecture**
On the evolutionary history of metastatic cancer
Kamila Naxerova, PhD

RECEPTION & KGCRF POSTER COMPETITION WINNERS ANNOUNCEMENT

Gordon Hall 106 Waterhouse Conference Room

5:15 – 6:30pm Reception

KEYNOTE SPEAKER

KAMILA NAXEROVA, PhD

Assistant Professor
Center for Systems Biology
Massachusetts General Hospital
Harvard Medical School

Kamila Naxerova received her B.Sc. in Molecular Biotechnology with a specialization in bioinformatics from Heidelberg University in Germany, and her Ph.D. in Human Biology and Translational Medicine from Harvard University in Cambridge, MA. She completed her postdoctoral training with Dr. Stephen J. Elledge at Harvard Medical School. The Naxerova uses computational and high-throughput experimental approaches to study the evolutionary history of normal and neoplastic tissues. Dr. Naxerova is a recipient of a Breakthrough Award from the U.S. Department of Defense, a NextGen Grant for Transformative Cancer Research from the American Association for Cancer Research, an Early Stage Investigator MERIT Award from the National Cancer Institute, a Howard M. Goodman Fellowship from the MGH Department of Molecular Biology and an Emerging Leader Award from the Mark Foundation for Cancer Research.